

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

(11) International Publication Number:

WO 93/05763

A61K 7/48

A1

(43) International Publication Date:

1 April 1993 (01.04.93)

(21) International Application Number:

PCT/JP92/01210

(22) International Filing Date:

22 September 1992 (22.09.92)

(30) Priority data:

3/243669 4/130699

24 September 1991 (24.09.91) JP

22 May 1992 (22.05.92)

(71) Applicant (for all designated States except US): KAO COR-PORATION [JP/JP]; 1-14-10, Nihonbashikayaba-cho, Chuo-ku, Tokyo 103 (JP).

(72) Inventors; and

(72) Inventors; and
(75) Inventors/Applicants (for US only): OHASHI, Yukihiro [JP/JP]; 30-19, Koedomachi, Utsunomiya-shi, Tochigi 321 (JP). FUJIMORI, Taketoshi [JP/JP]; NAGAI, Minoru [JP/JP]; 4594 Ichihana, Ichikaimachi, Haga-gun, Tochigi 321-34 (JP). KAWAMATA, Akira [JP/JP]; 3-1-17-707, Hanabusa, Utsunomiya-shi, Tochigi 320 (JP). 3-1-17-707, Hanabusa, Utsunomiya-shi, Tochigi 320 (JP). YADA, Yukihiro [JP/JP]; 1-115-1, Kugetanishi, Ninomiyamachi, Haga-gun, Tochigi 321-45 (JP). HIGUCHI, Kazuhiko [JP/JP]; 4594 Ichihana, Ichikaimachi, Hagagun, Tochigi 321-34 (JP). IMOKAWA, Genji [JP/JP]; 1022-89, Himuromachi, Utsunomiya-shi, Tochigi 321-32 (JP). TAKEMA, Yoshinori [JP/JP]; 2606-6, Akabane, Ichikaimachi, Haga-gun, Tochigi 321-34 (JP). SAKAI-NO, Yukiko [JP/JP]; 6-5-1-305, Motoimaizumi, Utsunomiya-shi, Tochigi 321 (JP). OGAWA, Ayumi [JP/JP]; 3322 Yamauchi, Motegimachi, Haga-gun, Tochigi 321-37 3322 Yamauchi, Motegimachi, Haga-gun, Tochigi 321-37 (JP). FUJIMURA, Tsutomu [JP/JP]; 4594 Ichihana, Ichikaimachi, Haga-gun, Tochigi 321-34 (JP).

(74) Agents: ARUGA, Mitsuyuki et al.; Kyodo Bldg., 3-6, Nihonbashiningyo-cho 1-chome, Chuo-ku, Tokyo 103 (JP).

(81) Designated States: US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).

Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COMPOSITION FOR EXTERNAL SKIN CARE

(1)

(57) Abstract

A composition for external skin care comprising an amine derivative represented by formula (1), wherein R1 is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, and R2, R3, R4, R5, and R6 are individually a hydrogen atom or a hydrocarbon group having 1-10 carbon atoms, which may be substituted or unsubstituted by one or more hydroxy groups; or an acid addition salt thereof, in an amount from 0.0001 to less than 0.1 % by weight; and a method of curing wrinkles and keratinization of the skin characterized by applying said amine derivative or its salt to the

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCI on the front pages of pamphlets publishing international applications under the PCT.

•					- · · · · · ·
		Fl	Finland	MN	Mongolia
Т	Austria	FR	France	MR	Mauritania
U	Australia	GA	Gabon	· MW	Malawi
В	Barhados	_	United Kingdom	NL	Netherlands
ε	Belgium	GB	_ ·	NO	Norway .
F	Burkina Faso	GN	Guinea	NZ	New Zealand
G	Bulgaria	GR	Greece	PL	Poland
U	Benin	HU	Hungary	PT	Portugul
R	Brazil	IE	Ireland	RO	Romania
:A	Canada	IT	Italy	RU	Russian Federation
F	Central African Republic	JP	Japan	SD	Sudan
.G	Congo	KР	Democratic People's Republic	SE	Sweden
CH CH	Switzerland		of Korea		Slovak Republic
 21	Côte d'Ivoire	KR	Republic of Korea	SK	•
	=	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	su	Soviet Union
. 22	Czechoslovakia	LU	Luxembourg	ďΤ	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE .	Germany	_		UA	Ukraine
DΚ	Denmark	MG	Madagascar	US	United States of America
ES	Spain	MI	Mali		

TITLE OF THE INVENTION

COMPOSITION FOR EXTERNAL SKIN CARE

Field of the Invention

The present invention relates to a composition for external skin care which enables the skin to maintain its normal functions and has an effect of curing keratinization and wrinkles of the skin.

Background Art

The skin prevents water and other various components in living bodies from being lost. It plays roles of preventing water from dissipating and of constantly maintaining a body temperature. Skin also functions as a barrier for protecting bodies from external physical and chemical stimulators (e.g., humidity, temperature, ultraviolet rays, etc.) and from various bacteria. Its physiological functions in the activities of living bodies are therefore very important. Keeping healthy and beautiful skin is also a subject of a great concern, especially, for female. Conditions of skin, however, are constantly affected by various factors such as humidity, temperature, ultraviolet rays, cosmetics, age, diseases, stress, food customs, and the like. A number of skin troubles, such as deterioration of various skin functions, aging of the skin, and the like, are caused by these factors. Among these, troubles such as dry skin, fatty skin, dandruff, and the like are caused by

thickening of the skin, incomplete keratinization, abnormal lipid metabolism, and the like resulting from the progress in turnover of epidermis which is induced by external and internal factors affecting the skin.

Major conventional methods of preventing the skin troubles and improving the skin have been preventing the skin from drying or promoting its moisture retention capability by the application of synthetic or natural moisturizing components, improving blood circulation in the skin by the application of blood circulation promoters, and the like.

These methods, however, involve various problems relating to their effects on the skin trouble prevention or the skin improvement, duration for which the effects last, stability and safety of drugs, and the like.

Development of a composition for external skin care which is safe and has a superior keratin improving effect has therefore been desired.

On the other hand, wrinkles are produced by aging of the skin due to senility, exposure to sun light, and the like. Cells constituting fibroblost synthesizing dermal fiber components decrease and become small due to exposure to sun light and along with age. Especially, a large amount of colagen fibers are lost, leading to dermal degeneration and reduction in the dermal fat organization, and finally to the skin aging. This is a major cause of wrinkles, atony, and loss of flexibility.

A number of compositions and methods have been proposed

for suppressing or curing aged skins such as wrinkles and the like (Japanese Patent Laid-open (ko-kai) Nos. 185005/1987, 502546/1987, 72157/1990, 288822/1990, etc.). Most of them, however, are not satisfactory in their effects of wrinkle improvement.

Vitamin A acid has been confirmed to exhibit a wrinkle curing effect [Journal of the American Academy of Dermatology, Vol. 25, No. 2, Part 1, 231-237 (August, 1991); ibid. Vol. 21, No. 3, Part 2, 638-644 (September, 1989); ibid. Vol. 19, No. 1, Part 2, 169-175 (July 1988); ibid. Vol. 15, No. 4, Part 2, (October, 1986)]. Vitamin A acid, however, has problems in its safety; e.g., it induces red spots on the skin, is irritative and teratogenic.

Development of a safe composition for external skin care exhibiting an excellent wrinkle curing effect has therefore been desired.

Some compounds among amine derivatives represented by the following formula (1),

$$R^{1}-O-CH_{2}$$
 $CH-OH$
 $R^{2}-N-CH_{2}$
 $R^{3}-C$
 R^{4}
 R^{5}
 R^{6}
 R^{6}

(wherein R^4 is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom or a

hydrocarbon group having 1-10 carbon atoms, either substituted or unsubstituted by 1 or more hydroxy groups) are known to be useful as an emulsifier [Journal of Colbid and Interface Science, Vol. 64, No. 2, 300-310 (1978), Japanese Patent Laid-open (ko-kai) No. 117421/1979]. It is also known that these compounds may be added to cosmetic compositions in an amount of 0.1-30% by weight [Japanese Patent Laid-open (ko-kai) Nos. 135233/1979 and 147937/1979]. However, there are no knowledge about the actions of said compounds (1) to the skin; especially their actions effected to dermal cells in the skin have not been known at all.

Based on the supposition that the wrinkles and keratinization of the skin are produced by abnormalities in functions of the skin organization, which are caused by various factors externally or internally affecting living bodies, such as environmental changes, e.g., change of climate, ultraviolet rays, etc., variations in physiological functions, e.g., those due to aging, diseases, etc.), the present inventors have studied various compounds as to (1) their capability of suppressing the progress in epidermal turnover, resulting in skin thickening, incomplete keratinization, abnormal lipid metabolism, etc., which are caused by ultraviolet rays, various components, etc.; and their capability of normalizing the keratinized skin, (2) their wrinkle improving capability, (3) their safety, and the like. As a result, the present inventors have found that amine derivatives of the above formula (1) and their

acid addition salts exhibit these capabilities even in a very small amount, and thus are useful as a component for compositions to be applied externally to the skin. The findings have led to the completion of the present invention.

Disclosure of the Invention

The present invention relates to a composition for external skin care comprising 0.0001-0.1% by weight of an amine derivative of the above formula (1) or its acid addition salt.

The present invention also relates to a method of improving wrinkles characterized by applying said amine derivative or its acid addition salt to the skin.

Furthermore, the present invention relates to a method of improving keratinization of the skin characterized by applying said amine derivative or its acid addition salt to the skin.

Brief Description of the Drawings

Figures 1 and 2 are drawings showing changes in the relative amount of $[^3H]$ thymidine incorporation due to the addition of the amine derivative of Example 1.

Figure 3 is a drawing showing changes in the transglutaminase activity due to the addition of the amine derivative of Example 2.

Figure 4 is a drawing showing changes in the skin thickness due to UVB irradiation and the addition of the amine derivative of Example 3.

Best Mode for Carrying out the Invention

In amine derivatives of formula (1), R1 represents a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms. Specific examples include hydrocarbon groups such as butyl, hexyl, octyl, decyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, octadecyl, docosyl, dotriacontyl, methyl-branched isostearyl, 2-ethylhexyl, 2-heptylundecyl, 5,7,7-trimethyl-2-(1,3,3-trimethylbutyl)-octyl, 9octadecenyl, 9,12-octadecadienyl, cyclohexyl, phenyl, benzyl, cholesteryl, and the like. R^2 , R^3 , R^4 , R^5 , and R^6 individually represent a hydrogen atom or a hydrocarbon group having 1-10 carbon atoms, which may be substituted or unsubstituted by 1 or more hydroxy groups. examples are hydrogen atom and hydrocarbon groups such as methyl, ethyl, butyl, hexyl, phenyl, benzyl, hydroxymethyl, hydroxyethyl, 1,2-dihydroxyethyl, 1,2,3-trihydroxypropyl, 1,2,3,4-tetrahydroxybutyl, 1,2,3,4,5-pentahydroxypentyl, and the like.

Among these amine derivatives (1), those having a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms for \mathbb{R}^1 , a hydrogen atom, a lower alkyl, or a lower hydroxyalkyl for \mathbb{R}^2 , and hydrogen atoms for \mathbb{R}^3 , \mathbb{R}^4 , \mathbb{R}^5 , and \mathbb{R}^6 are preferable.

As preferable examples of \mathbb{R}^1 , linear, branched, or cyclic alkyl or alkenyl groups having 4-40 carbon atoms are

given, and among them, especially preferred are methylbranched alkyl groups of the following formula,

$$CH_3(CH_2)_mCH(CH_2)_n-CH_3$$

wherein m+n is 11-17, m is 4-10, n is 5-11. Particularly preferred are mixtures of compounds (described at Synthetic Example 3) of formula (1) having the above methyl-branched alkyl groups for R¹, in which m+n is 11-17, m is 4-10 and n is 5-11, with the distribution peak at m=7 and n=8.

Amine derivatives (1) of the present invention can be synthesized by various methods known in the art. For example, they can be synthesized by the addition of an amine derivative (3) to a glycidyl ether derivative (2) according to the following reaction formula.

wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 have the same meanings as defined above.

As required, the amine derivative (1) thus obtained can be converted into a salt of inorganic acid, e.g., hydrochloric acid, sulfuric acid, nitric acid, phosphoric

acid, etc., or a salt of organic acid, e.g., succinic acid, fumaric acid, hexadecanoic acid, octadecanoic acid, lactic acid, glycolic acid, citric acid, tartaric acid, benzoic acid, etc., according to a conventional method.

These amine derivatives (1) and their acid addition salts exhibit actions of suppressing production of wrinkles and extinguishing wrinkles, as shown in Examples hereinafter.

Furthermore, as shown in Examples hereinafter, said amine derivatives (1) and their acid addition salts exhibit excellent effects of controlling synthesis of epidermal cell DNA, exhibiting, in both in vivo and in vitro experiments, their differentiation inducing activity and epidermal thickening controlling effects. Therefore, they possess an action of normalizing abnormal keratinization of epidermal cells in the skin.

Although said amine derivatives (1) and their acid addition salts may exhibit their effects by oral administration, a more desirable method for curing wrinkles and keratinization is to apply their effective amounts to the skin.

In the case where said amine derivative (1) or its acid addition salt is used by applying it to the skin, it is desirable that the compound be formulated into a composition for external skin care in an amount of from 0.0001 to less than 0.1% by weight and the composition be applied to the skin. The composition for external skin care may take

various forms for use, such as pharmaceutical compositions for external skin care, cosmetics, and the like. Given as examples of pharmaceutical compositions for external skin care are various ointment compositions comprising the amine derivative (1) or its acid addition salt and other pharmaceutical components. As ointments, both those containing an oily base as a base and those containing an oil-in-water or water-in-oil emulsion-type base as a base can be used. There are no limitations as to the types of oily bases. Examples include vegetable oils, animal oils, synthetic oils, fatty acids, natural or synthetic glycerides, and the like. No special limitations are imposed to said other pharmaceutical components. example, analgesic and antiphlogistic agents, antipruritics, disinfectants, astringents, emollients, hormones, vitamins, and the like may be used suitably as needed.

Where used as a cosmetic composition, it is possible to incorporate any commonly used cosmetic components, such as oils, moisturizers, UV absorbents, alcohols, chelating agents, pH modifiers, preservatives, thickeners, coloring agents, perfumes, and the like, in any optional combinations.

Cosmetic compositions may be prepared into a various forms depending on their uses; they may be water-in-oil or oil-in-water type emulsified cosmetics, creams, cosmetic milky lotions, lotions, oily cosmetics, facial packs, foundations, or the like. These compositions for external

skin care may be prepared into the above various forms according to conventional methods.

Examples

The present invention is hereinafter described in detail by way of examples, which should not be construed to be limiting thereof.

Synthetic Example 1

Synthesis of 1-(2-hydroxyethylamino)-3-tetradecyloxy-2-propanol [In formula (1), $R^1=C_{14}H_{29}$ -, $R^2=R^3=R^4=R^5=R^6=H$]

To a 3 1 5-necked flask equipped with a stirrer, dropping funnel, thermometer, nitrogen inlet tube, and condenser were charged 916.2 g (15 mol) of ethanolamine, and 183 g of ethanol. 270.5 g (1 mol) of tetradecylglycidyl ether was dropped to the mixture over 3 hours, while stirring and heating at 80°C under a nitrogen atmosphere. After the addition, the ethanol and excess ethanolamine were removed by evaporation under reduced pressure. The residue was crystallized from methanol to obtain 295.7 g of colorless powder of the title compound (1a) (yield: 89.2%).

Synthetic Example 2

Amine derivatives (1b)-(1f) were prepared in the same manner as in Synthetic Example 1.

(1f)

Synthetic Example 3

ОH

Synthesis of 1-(2-hydroxyethylamino)-3-(methyl-branched-isostearyl)-2-propanol [In formula (1), R^1 =methyl-branched-isostearyl, $R^2=R^3=R^4=R^5=R^6=H$]

To a 3 l 5-necked flask equipped with a stirrer, dropping funnel, thermometer, nitrogen inlet tube, and

condenser were charged 916.2 g (15 mol) of ethanolamine, and 183 g of ethanol. 326.6 g (1 mol) of methyl-branched-isostearylglycidyl ether was dropped to the mixture over 3 hours, while stirring and heating at 80°C under a nitrogen atmosphere. After the addition, the ethanol and the excess ethanolamine were removed by evaporation under reduced pressure. The residue was purified by silica gel flush chromatography to obtain 320.5 g of light yellow paste of the title compound (1g) (yield: 82.7%).

$$CH_3(CH_2)_mCH(CH_2)_nO$$
 OH (1g)

wherein m+n is 11-17, m is 4-10 and n is 5-11, with the distribution peak at m=7 and n=8.

Synthetic Example 4

Synthesis of 1-(2-hydroxyethylamino)-3-(methyl-branched-isostearyl)-2-propanol hydrochloride

2.83 ml (34 mmol) of 12 N hydrochloric acid was added to a solution of 13.2 g (34 mmol) of amine derivative (1g) prepared in Synthetic Example 3 in 100 ml of ethanol, followed by evaporation of the solvent, to prepare 14.4 g of light yellow gel of the title hydrochloride (1g') of amine derivative (1g).

Synthetic Example 5

1-(2-hydroxyethylamino)-3-(9-octadecenyloxy)-2-propanol
(1h) was prepared in the same manner as in Synthetic Example

PCT/JP92/01210


WO 93/05763

З.

Synthetic Example 6

Synthesis of 1-(2-hydroxyethylamino)-3-phenyloxy-2-propanol [In formula (1), R^1 =phenyl, R^2 = R^3 = R^4 = R^5 = R^6 =H]

To a 500 ml 4-necked flask equipped with a stirrer, dropping funnel, thermometer, nitrogen inlet tube, and condenser were charged 91.6 g (1.5 mol) of ethanolamine and 20 g of ethanol. 15.0 g of phenylglycidyl ether was dropped to the mixture over 2 hours, while stirring and heating at 80°C under a nitrogen atmosphere. After the addition, the ethanol and the surplus ethanolamine were evaporated under reduced pressure. The residue was subjected to vacuum distillation (175-180°C, 0.5 Torr) to obtain 18.5 g of colorless solid of the title compound (1i) (yield: 86.7%).



Synthetic Example 7

Synthesis of 1-[bis(hydroxyethylamino)]-3-tetradecyloxy-2-propanol [In formula (1), $R^1=C_{14}H_{29}$ -, $R^2=-CH_2CH_2OH$, $R^3=R^4=R^5=R^6=H$]

To a 1 1 5-necked flask equipped with a stirrer,

dropping funnel, thermometer, and nitrogen inlet tube were charged 105.1 g (1 mol) of diethanolamine and 100 g of ethanol. 270.5 g of tetradecylglycidyl ether was dropped to the mixture over 30 minutes, while stirring and heating at 80°C under a nitrogen atmosphere. After the addition, the mixture was stirred for a further 6 hours. The reaction mixture thus prepared was purified by silica gel flush chromatography to obtain 232.0 g of light yellow oil of the title compound (1j) (yield: 61.8%).

$$C_{14}H_{29}$$
OH (1j)

Synthetic Example 8

Amine derivatives (1k)-(1o) were prepared in the same manner as in Synthetic Example 7.

$$C_{16}^{H_{33}O}$$
 OH (1n)

Synthetic Example 9

Synthesis of

1-(2,3-dihydroxypropylamino)]-3-tetradecyloxy-2-propanol (1p) [In formula (1), $R^1=C_{14}H_{29}$ -, $R^2=R^3=R^4=R^5=H$, $R^6=-CH_2OH$]

To a 2 1 4-necked flask equipped with a stirrer, dropping funnel, thermometer, and nitrogen inlet tube were charged 25 g (0.27 mol) of 3-amino-1,2-propanediol and 100 g of ethanol. 9.9 g (0.037 mol) of tetradecylglycidyl ether was dropped to the mixture over 3 hours, while stirring and heating at 80°C under a nitrogen atmosphere. After the addition, the mixture was stirred for a further 1 hour. 1 l of water was added to the reaction mixture thus prepared to obtain a solid material by filtration. The solid was crystallized from methanol to obtain 10.3 g of colorless powder of the title compound (lp) (yield: 77.8%).

Synthetic Example 10

Amine derivatives (1q)-(1s) were prepared in the same manner as in Synthetic Example 9.

$$C_{16}^{H_{33}O}$$
 OH (1s)

Synthetic Example 11

Amine derivatives (1t)-(1x) were prepared in the same manner as in Synthetic Example 1.

Synthetic Example 12

Amine derivatives (1y)-(1z) were prepared in the same manner as in Synthetic Example 3.

$$C_9H_{19}$$
 C_7H_{15}
OH

(12)

Synthetic Example 13

Amine derivatives (laa)-(lab) were prepared in the same

manner as in Synthetic Example 7.

$$CH_3(CH_2)_mCH(CH_2)_n$$
—OH (1aa)
 CH_3 HO \sim HN—OH

In the above formulas (1aa)-(1ac), m+n is 11-17, m is 4-10 and n is 5-11, with the distribution peak at m=7 and n=8. Synthetic Example 14

Amine derivatives (lad)-(laf) were prepared in the same manner as in Synthetic Example 9.

$$C_{14}H_{29}O$$
 —OH (1ad)

$$C_{14}H_{29}O$$
 — OH (laf)

Substituents R^1-R^6 in amine derivatives of formulas (la)-(laf) are listed in Tables 1-3.

TABLE 1

	Substituent						
Compound	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	
(1a)	C ₁₄ H ₂₉	Н	Н	Н	H	H	
(1b)	C ₁₀ H ₂₁	н	Н	H	H	H	
(1c)	C ₁₂ H ₂₅	H	H	H	H	H	
(1d)	C ₁₆ H ₃₃	н	H	H	H	H	
(le)	C ₁₈ H ₃₇	H	H	Н	Н	H	
(1f)	cholesteryl	Н	H	Н	H	H	
(1g)	methyl-branched isostearyl Me	i H	H	н	н	н	
(1h)	oleyl	Н	Н	н	Н	Н	
(li)	\bigcirc	H	Н	Н	H	Н	
(1j)	C ₁₄ H ₂₉	-сн ₂ сн ₂ он	н	н	H	Н	
(1k)	C ₁₄ H ₂₉	CH ₃	H	H	H	Н	
(11)	. C ₁₄ H ₂₉	-CH ₂ -(O)	Н	H	Н	Н	

TABLE 2

	Substituent						
Compound	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	
(1m)	C ₁₄ H ₂₉	CH ₃	H .	н	-CH-OH CH-OH CH-OH CH ₂ -OH	н	
(ln)	C ₁₆ H ₃₃	-CH ₂ -(O)	H	H	-сн ₂ -он -сн-он	н	
(10)	C ₁₆ H ₃₃	-CH ₂ -	н	H	 CH-OH CH-OH CH ₂ -OH	н	
(1p)	C ₁₄ H ₂₉	H	н	н	-cн ₂ он	H	
(1q)	C ₁₆ H ₃₃	н .	Н	Н	-сн ₂ он -сн-он	H	
(1r)	C ₁₆ H ₃₃	H	н	н	CH-OH	н	
(1s)	C ₁₆ H ₃₃	н -	сн ₂ он	-CH2-OF	Сн ₂ -Он н н	н	

TABLE 3

·	Substituent						
Compound	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	
(lt)	////	н	Н	Н	Н	H	
(lu)	C ₁₁ H ₂₃	H	H	H	H	H	
(1v)	C ₁₃ H ₂₇	Н	H	H	H	H	
(lw)	C ₁₅ H ₃₁	Н	H	H	H	H	
(lx)	C ₁₇ H ₃₅	H	H	H	H	H	
(ly)		н	H	H	H	H	
(1z)	С ₉ н ₁₉ снсн ₂ С ₇ н ₁₅						
(laa)	methyl-branched isostearyl		•				
	Me	-сн ₂ сн ₂ он	н	Н	H	H	
(lab)	methyl-branched isostearyl Me	-СН3	н	Н	н	н	
(lac)	methyl-branched isostearyl						
·	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	-CH ₂ -) н	н	Н	Н	
(lad)	C ₁₄ H ₂₉	H	-CH ₂ OH	-CH ₃	H	H	
(lae)	C ₁₄ H ₂₉	H	-СН ₂ ОН	-CH ₂ OH	н н	H	
(laf)	C ₁₄ H ₂₉	Н	H	H	-CH ₃	H	

Properties, melting points, and IR and NMR data of amine derivatives (la)-(laf) obtained are as follows.

(la) Colorless powder:

(m.p. 69.1-69.5°C)

IR (KBr, cm⁻¹) 3448, 2920, 2852, 1464, 1374, 1330, 1120, 1090, 1054.

 $1_{\text{H-NMR}(\text{CDCl}_3, \delta)}$ 0.67-1.87(m, 27H), 2.53-2.90(m, 4H), 2.93-3.20(br, 3H), 3.30-4.07(m, 7H).

(1b) Colorless powder:

m.p. 52.7-53.8°C

IR (KBr, cm⁻¹) 3452, 2920, 2852, 1466, 1432, 1380, 1358, 1332, 1120, 1050, 870.

¹H-NMR(CDCl₃, δ) 0.63-1.97(m, 19H), 2.52-3.22(m, 7H),

3.25-4.10(m, 7H).

(1c) Colorless powder:

m.p. 60.2-61.5°C

IR (KBr, cm⁻¹) 3452, 2920, 2852, 1464, 1356, 1382, 1120, 1050, 958, 872.

 $1_{\text{H-NMR}(CDCl}_3, \delta)$ 0.63-1.80(m, 23H), 2.54-2.96(m, 7H), 3.26-4.13(m, 7H).

(1d) Colorless powder:

(m.p. 70.6-71.2°C)

IR (KBr, cm^{-1}) 3448, 2920, 2852, 1462, 1124, 1050.

1_{H-NMR}(CDCl₃, δ) 0.67-1.67(m, 31H), 2.60-2.80(m, 4H), 3.10-3.90(m, 10H).

(le) Colorless powder:

PCT/JP92/01210

WO 93/05763

```
(m.p. 77.8-78.3°C)
                        3452, 2920, 2852, 1464, 1376, 1360,
   IR (KBr, cm^{-1})
                        1330, 1120, 1052, 868.
                        0.67-1.90(m, 35H), 2.13-3.11(m, 7H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        3.30-4.13(m, 7H).
(1f) Colorless powder:
   (m.p. 177.6-178.9°C)
                        3456, 3376, 2936, 2912, 1458, 1368,
   IR (KBr, cm^{-1})
                        1096, 1052, 948, 860.
                        0.68(s, 3H), 0.84-1.72(m, 32H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        1.72-2.48(m, 7H), 2.66-2.96(m, 7H),
                        3.06-3.26(m, 1H), 3.36-3.58(m, 2H),
                        3.67(bt, J=5.0Hz, 2H), 3.80-3.96(m,
                        1H), 5.32-5.38(m, 1H).
(1q) Light yellow paste:
                        3440, 2924, 2856, 1462, 1380, 1118,
   IR ( NaCl, cm^{-1})
                        1054.
                        0.65-1.80(m, 35H), 2.38-2.92(m, 4H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        3.18-4.22(m, 10H).
(lq') Light yellow gel:
                        3344, 2920, 2856, 1588, 1460, 1376,
   IR ( NaCl, cm^{-1})
                        1092.
                        0.62-1.93(m, 35H), 2.90-3.83(m, 10H),
   ^{1}H-NMR(CDCl_{3}, \delta)
                        3.83-4.67(m, 5H).
(1h) Light yellow solid:
   (m.p. 36.0-37.2°C)
   IR ( NaCl, cm^{-1}) 3344, 2928, 2856, 1462, 1352, 1326,
```

1112, 1058.

 $1_{H-NMR}(CDCl_3, \delta)$ 0.76-2.33(m, 33H), 2.60-2.93(m, 4H), 3.13-4.20(m, 10H), 5.23-5.67(m, 2H).

(li) Colorless solid:

(m.p. 77.0-78.4°C)

IR (KBr, cm⁻¹) 3308, 2872, 1596, 1496, 1440, 1244, 1062, 1044, 956, 856, 754, 698.

1_{H-NMR}(CDCl₃, δ) 2.70-2.90(m, 4H), 3.44(bs, 3H),
3.70(bt, J=5.0Hz, 2H),
3.94(d, J=5.3Hz, 2H),
4.06-4.20(m, 1H), 6.85-7.00(m, 3H),
7.22-7.34(m, 2H).

(1j) Light yellow oil:

IR (NaCl, cm⁻¹) 3364, 2924, 2856, 1460, 1376, 1118, 1076, 1040.

1_{H-NMR}(CDCl₃, δ) 0.89(t, J=6.5Hz, 3H), 1.10-1.75(m, 24H), 2.34-2.95(m, 6H), 3.24-4.06(m, 9H), 4.61(br, 3H).

(1k) Light yellow oil:

IR (NaCl, cm⁻¹) 3404, 2928, 2856, 1462, 1118, 1080, 1036, 752.

1_{H-NMR}(CDCl₃, δ) 0.88(t, J=6.5Hz, 3H), 1.12-1.72(m, 24H), 2.30-2.77(m, 7H), 3.09(br, 2H), 3.33-3.54(m, 4H), 3.60-3.70(m, 2H), 3.85-4.00(m, 1H).

(11) Light yellow oil:

PCT/JP92/01210

```
IR ( NaCl, cm^{-1}) 3404, 2928, 2856, 1456, 1378, 1114, 1068, 736, 698.
```

1_{H-NMR}(CDCl₃, δ) 0.89(t, J=6.5Hz, 3H), 1.09-1.70(m, 27H), 2.55-3.08(m, 6H), 3.25-4.04(m, 9H), 7.18-7.40(m, 5H).

(lm) Colorless solid:

(m.p. 88.9-90.2°C)

IR (KBr, cm⁻¹) 3360, 2924, 2852, 1468, 1348, 1244, 1126, 1100, 1084, 1042.

 $1_{H-NMR(CDC1_3, \delta)}$ 0.88(t, J=6.5Hz, 3H), 1.20-1.80(m, 27H), 2.27-2.86(m, 7H), 3.30-4.02(m, 11H), 4.57(br, 5H).

(ln) Light yellow oil:

IR (NaCl, cm^{-1}) 3388, 2920, 2856, 1470, 1110, 1074, 1036, 1026, 744, 702.

1_{H-NMR}(CDCl₃, δ) 0.88(t, J=6.5Hz, 3H), 1.16-1.72(m, 28H), 2.46-2.82(m, 4H), 3.22-4.00(m, 13H).

(10) Light yellow oil:

IR (NaCl, cm^{-1}) 3352, 2928, 2856, 1458, 1118, 1088, 1054, 1042, 756, 702.

 1 H-NMR(CDCl₃, D₂O, δ) 0.86(t, J=6.5Hz, 3H), 1.08-1.80(m, 28H), 2.38-2.90(m, 4H), 3.13-4.13(m, 13H), 7.14(br, 5H).

(lp) Colorless powder:

(m.p. 100.5-102.2°C)

IR (KBr, cm^{-1}) 3388, 2920, 2852, 1470, 1352, 1124,

1076.

1_{H-NMR}(CDCl₃, δ) 0.88(t, J=6.5Hz, 3H), 1.05-1.67(m, 24H), 1.68-2.20(m, 4H), 2.58-2.94(m, 4H), 3.31-3.96(m, 8H).

(1q) Colorless powder:

(m.p. 98.4-99.5°C)

IR (KBr, cm⁻¹) 3440, 2920, 2852, 1468, 1344, 1124, 1096, 1064.

1_{H-NMR(CDCl₃, δ)} 0.88(t, J=6.5Hz, 3H), 1.13-1.67(m,
28H), 2.30-2.97(m, 8H), 3.30-4.00(m,
8H).

(1r) Colorless powder: (m.p. decomposed, not measurable)

IR (NaCl, cm⁻¹) 3352, 2928, 2856, 1470, 1458, 1118, 1088, 1054, 1042, 756, 702.

1_{H-NMR}(CDCl₃, D₂O, δ) 0.86(t, J=6.5Hz, 3H), 1.08-1.80(m, 28H), 2.38-2.90(m, 4H), 3.13-4.13(m, 13H), 7.14(br, 5H).

(1s) Colorless powder:

(m.p. 85.7-87.1°C)

IR (KBr, cm⁻¹) 3488, 2924, 2852, 1470, 1334, 1120, 1036.

 $1_{H-NMR(MeOH-d_4, \delta)}$ 0.67-1.93(m, 31H), 2.50-2.94(m, 2H), 3.17-3.98(m, 13H).

(1t) Colorless powder:

(m.p. 50.3-51.2°C)

IR (KBr, cm⁻¹) 3448, 2920, 2848, 1464, 1425, 1359, 1116, 1047, 957, 912, 867.

```
^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        1.18-1.75(m, 14H),
                        1.95-2.12(m, 2H), 2.55-2.84(m, 4H),
                        3.02(brs, 3H), 3.32-3.52(m, 4H),
                        3.60-3.74(m, 2H), 3.82-3.98(m, 1H),
                        4.85-5.07(m, 2H), 5.68-5.94(m, 1H).
(lu) Colorless powder:
   (m.p. 61.2-62.1°C)
   IR (KBr, cm^{-1})
                        3448, 2920, 2852, 1466, 1120, 1052.
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        0.80-0.98(m, 3H),
                        1.18-1.70(m, 18H), 2.54-2.85(m, 4H),
                        3.05-4.00(m, 10H).
(1v) Colorless powder:
   (m.p. 67.4-68.4°C)
   IR (KBr, cm^{-1})
                        3444, 2920, 2848, 1464, 1358, 1332,
                        1120, 1090, 1050, 952, 868, 722.
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        0.88(t, J=6.24Hz, 3H),
                        1.10-1.70(m, 22H), 2.54-3.20(m, 7H),
                        3.30-3.52(m, 4H), 3.58-3.74(m, 2H),
                        3.80-3.98(m, 1H).
(1w) Colorless powder:
   (m.p. 72.2-73.4°C)
   IR (KBr, cm^{-1})
                        3448, 2920, 2852, 1464, 1378, 1328,
                        1122, 1052, 956, 866, 720.
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        0.88(t, J=6.19Hz, 3H),
                        1.08-1.70(m, 26H), 2.50-3.20(m, 7H),
                        3.28-3.50(m, 4H), 3.58-3.72(m, 2H),
                        3.80-3.98(m, 1H).
```

```
(lx) Colorless powder:
  (m.p. 77.4-78.0°C)
                       3440, 3312, 2916, 2852, 1464, 1378,
  IR (KBr, cm^{-1})
                        1356, 1330, 1120, 1052, 954, 868, 720.
                       0.88(t, J=6.24Hz, 3H),
   ^{1}H-NMR(CDCl_{3}, \delta)
                        1.10-1.70(m, 30H), 2.50-3.25(m, 7H),
                        3.32-3.52(m, 4H), 3.62-3.72(m, 2H),
                        3.82-3.98(m, 1H).
(ly) Light yellow oil:
                        3388, 2926, 2856, 1461, 1377, 1110.
   IR ( NaCl, cm^{-1})
                        0.70-0.97(m, 15H),
   ^{1}H-NMR(CDCl_{3}, \delta)
                        0.98-1.76(m, 20H), 2.56-2.73(m, 4H),
                        3.29-3.59(m, 4H), 3.62-4.10(m, 6H).
(lz) Light yellow oil:
                        3296, 2924, 2856, 1458, 1374, 1118,
   IR ( NaCl, cm^{-1})
                        1052, 940, 884.
                        0.70-0.98(m, 15H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        0.98-1.78(m, 20H), 2.56-2.92(m, 4H),
                        3.30-3.60(m, 4H), 3.62-4.10(m, 6H).
(laa) Light yellow oil:
                        3356, 2924, 2856, 1464, 1376, 1122,
   IR ( NaCl, cm^{-1})
                        1070.
                        0.78-1.00(m, 6H),
   1_{H-NMR}(CDC1_3, \delta)
                        1.00-1.75(m, 29H), 2.32-2.88(m, 6H),
                        3.30-4.00(m, 9H), 4.90(brs, 3H).
(lab) Light yellow oil:
                        3424, 2928, 2856, 1460, 1378, 1116,
   IR ( NaCl, cm^{-1})
```

```
1040.
                        0.72-0.96(m, 6H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        1.00-1.76(m, 29H), 2.33(s, 3H),
                        2.36-2.72(m, 4H), 3.30-3.52(m, 6H),
                        3.57-3.68(m, 2H), 3.82-3.96(m, 1H).
(lac) Light yellow oil:
   IR ( NaCl, cm^{-1})
                        3388, 2924, 2856, 1454, 1370, 1118.
                        0.63-1.92(m, 35H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        2.40-4.06(m, 15H), 7.18(brs, 5H).
(lad) Colorless powder:
   (m.p. 93.6-94.5°C)
                        3404, 2924, 2852, 1470, 1350, 1120,
   IR (KBr, cm^{-1})
                        1102, 1050.
                        0.80-1.00(m, 6H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                        1.10-1.68(m, 24H), 2.45-2.74(m, 2H),
                        3.20-3.64(m, 12H), 3.78-3.98(m, 1H).
(lae) Colorless powder:
   (m.p. 84.4-85.4°C)
                        3308, 2924, 2856, 1466, 1378, 1114.
   IR (KBr, cm^{-1})
                        0.80-1.00(m, 3H),
   ^{1}H-NMR(CDCl<sub>3</sub>, \delta)
                         1.10-1.70(m, 24H), 2.56-2.74(m, 2H),
                         3.24-3.74(m, 15H), 3.88-4.06(m, 1H).
(laf) Colorless powder:
   (m.p. 79.5-81.2°C)
                        3424, 3148, 2914, 2848, 1467, 1347,
   IR (KBr, cm^{-1})
                         1110, 1029, 969, 870.
                         0.88(t, J=6.4Hz, 3H), 1.15(d, J=6.1Hz,
   ^{1}H-NMR(CDCl_{3}, \delta)
```

3H), 1.21-1.73(m, 24H), 2.38-2.90(m, 7H), 3.30-3.60(m, 4H), 3.72-4.01(m, 2H).

EXample 1

Effect of amine derivative to wrinkles of hairless mouse produced by UVB radiation

(1) UVB light was irradiated on hairless mice (HR/ICR, 9 week age at the start of the experiment), 3 times a week, using 6 Toshiba health light lamps 20SE. The energy amount was measured by UV-Radiometer UVR-305/365D manufactured by Tokyo Optical Co. One irradiation was less than 1 MED; 65 mj with an energy amount of 0.28 mW/cm². After confirming production of wrinkles on the back of the hairless mice by irradiation of 20 weeks, the mice were divided into 8 groups. 80 μl of a 0.005% ethanol solution of amine derivative (lg) was applied for 6 weeks, 5 times a week. For a control group, 80 μl of ethanol was applied in the same way.

After the completion of the application, the degree of wrinkles was evaluated by the following criterion (wrinkle index). The results are shown in Table 4.

(Wrinkle degree)

- 1. No coarse wrinkle.
- 2. A few shallow coarse wrinkles across back.
- Same coarse wrinkles across back.
- 4. Several deep coarse wrinkles across back.

TABLE 4

Group	Wrinkle index
Control	3.75±0.09
Amine derivative (1g)	2.94±0.09

As clear from Table 4, the application of amine derivative (1g) could extinguish wrinkles developed on the back of hairless mice.

(2) In order to analyze the details of wrinkles, skin replicas with a diameter of 1 cm² were taken from 3 sites for each mouse, by using a hydrophilic exaflex vinyl silicone image duplicator. The replicas were horizontally placed to irradiate a light from a direction of 30° in angle. Percentage of shades emerged with by wrinkles in total area of the replica was determined by an image analyzer. The results are shown in Table 5.

TABLE 5

Group	Area percentage by image analysis (%)
Control	6.42±0.63
Amine derivative (1	g) 2.71±0.35

As can be seen from Table 5, the application of amine derivative (1g) could extinguish wrinkles developed on the back of hairless mice.

Example 2

Effect of amine derivatives (1) to the suppression of epidermal keratinized cell DNA synthesis

PCT/JP92/01210

(1) Method

- a) Cultivation of human epidermal keratinocytes

 Human epidermal keratinocytes (trademark: Epipack) sold

 by Kurabo Co. was used. A medium for human normal

 keratinocytes (trademark: K-GM) sold by the same company was

 used for the subsistence and subculture of the cells.
 - b) Measurement of DNA synthesis (Measurement of thymidine incorporation)

Keratinocytes cultivated under the proliferating conditions in a 24-well plate were used. First, the medium in each well was removed by aspiration, and replaced by the addition of 450 μ l of K-GM to which no pituitary extract was added, followed by the addition of amine derivatives (la)-(laf) obtained in above Synthetic Examples. Then, after the addition of 0.2 μ Ci/ml [³H]-thymidine over time, the mixture was incubated for 4 hours. The supernatant was removed by aspiration and the residue was washed 3 times with PBS(-), followed by the addition of 500 μ l of 2N NaOH. After incubation at 37°C for 10 minutes, the mixture was neutralized with the equivalent amount of 2N HCl. After the addition of 4 ml of ice-cold 10% trichloroacetic acid, the mixture was allowed to stand for 30 minutes.

Precipitate was collected by filtration through a glass filter and washed 3 times with 3 ml of ice-cold 10% trichloroacetic acid. The glass filter was washed once more with 3 ml of ice-cold ethanol, dried in air, and submitted to the measurement of the radio activity by a liquid

scintillation counter to calculate thymidine taken into the cells.

(2) Results

Figures 1 and 2 show the relative amount of [3 H] thymidine incorporation (%) when amine derivatives (1a)-(1af) at 10 μ M (upper row) and 100 μ M (lower row).

These figures clearly show that the thymidine intake is remarkably reduced by the addition of the above amine derivatives, that is, synthesis of epidermal keratinocytes DNA is inhibited.

Example 3

Effect of amine derivatives on transglutaminase activity of epidermal keratinocytes

(1) Measurement of transglutaminase activity

Keratinocytes cultivated under the proliferating conditions in a 6-well plate were used. The medium in each well was removed by aspiration, and replaced by the addition of 2 ml of K-GM to which no pituitary extract was added, followed by the addition of amine derivatives (la) and (lg). After 24 hours, each well was washed 3 times with PBS(-). Cells were collected by releasing them from the wells by rubber policeman. The cell suspension thus obtained was centrifuged at 2,500 rpm for 10 minutes to collect a precipitate. After the addition of 200 µl of buffer solution (a) [10 mM Tris-HCl buffer, 10 mM DTT, 0.5 mM EDTA; pH 7.4], the mixture was ultrasonicated 2 times, for 1 minute each time. The suspension thus obtained was

subjected to ultracentrifuge for 30 minutes at 25,000 rpm to obtain a supernatant. The supernatant was divided into portions of a specified amount. To each portion was added a reaction solution [a mixed solution of 300 mM Tris-HCl buffer, pH 8.1; 60 mM CaCl₂, 100 µl; 30 mM DTT, 100 µl; distilled water containing 540 µg of dimethylcasein, 100 µl; 12 mM putrescine, 50 µl; 2.5 µCl[¹⁴C]-putrescine, 50 µl; and distilled water, 100 µl] and the mixture was incubated at 37°C for 1 hour. Then, after the addition of 600 µl of 10% trichloroacetic acid, the mixture was allowed to stand still for 30 minutes. The precipitate was collected by using 0.45 µm nitrocellulose membrane. The membrane was washed with 15 ml of ice-cooled 5% trichloroacetic acid (containing 1% putrescine). The radio activity of the substance on the membrane was measured by a liquid scintillation counter.

(2) Results

Figure 3 shows the transglutaminase activities (cpm) when 1 μ M, 10 μ M, and 100 μ M of amine derivatives were added. The activity values increase to a value as much as about 3.0 times for the value of the control along with the increase in the amounts of amine derivatives added. This is an evidence that said amine derivatives possess a differentiation inducing activity for keratinocytes.

Example 4

Effect of amine derivatives on the control of dermal thickening

(1) Method

UVB (2-3 Med) was irradiated to hair-cut ears of 25 white guinea pigs, aged 4-6 weeks, and starting immediately after the irradiation squalane solutions containing 0.05% amine derivatives (1a) or (1g) were applied, once a day, for 1 week.

After 1 week, ears of guinea pigs were cut out to prepare skin organization specimens. A microscopic photograph was taken for each organization sample to measure the epidermal thicknesses, thus evaluating the effects of the sample compounds on the control of thickening by the UVB irradiation.

(2) Results

Figure 4 shows the results of the dermal thickness measurement on a sample to which UVB was irradiated, a sample to which amine derivative (la) was applied after the UVB irradiation, and a sample to which amine derivative (lg) was applied after the UVB irradiation. The concentration of each sample was 0.05%. The results demonstrate that these amine derivatives have an effect of controlling epidermal thickening.

Example 5

Preparation of W/O Cream

	·	% by weight
(1)	Amine Derivative (la)	0.01
(2)	Cholesterol	0.5
(3)	Cholesterol isostearate	1.0

		PCT/JP92/01210
WO 93/0:	5763	*
		·
(4)	Polyether-modified silicone	1.5
	Cyclic silicone	20.0
(5)	Methylphenyl polysiloxane	2.0
(6)		2.0
(7)	Methyl polysiloxane	0.5
(8)	Magnesium sulfate	
(9)	55% Ethanol	5.0
(10) Carboxymethyl chitin (Chitin liquid HV, manufactured by Ichimaru Farcos Co.)	0.5
(11) Purified water	Balance
÷-	(1)-(7) were heated to 80°C to dissolve.	(8)-(11) were
		to produce a

added to the mixture and homogeneously blended to produce a W/O cream.

Example 6

Preparation of O/W Cream

	% by weight
Polyoxyethylene (10) hydrogenated castor oil	1.0
Sorbitan monostearate	0.5
Sodium stearoyl methyltaurine	0.5
	2.0
	1.8
	0.001
	1.5
	1.0
•	8.0
	5.0
Glycerine	5.0
	Sorbitan monostearate Sodium stearoyl methyltaurine Cetostearyl alcohol Stearic acid Amine Derivative (1g) Cholesterol Cholesteryl isostearate Dicapric acid neopentyl glycol Methyl polysiloxane

(12) Purified water

Balance

(1)-(10) were heated to 80°C to dissolve. (11)-(12) were added to the mixture and homogeneously blended to produce an O/W cream.

Example 7

Preparation of moisturizing sunscreen cream

		% by weight
(1)	Amine Derivative (lg)	0.005
(2)	Silicone coated zinc oxide	7.0
(3)	2-Ethylhexyl p-methoxycinnamate	3.0
(4)	Cholesteryl isostearate	1.0
(5)	Polyether-modified silicone	2.0
(6)	Methyl polysiloxane	5.0
(7)	Cyclic silicone	15.0
(8)	Magnesium sulfate	1.0
(9)	Glycerine	5.0
(10)	Purified water	Balance

(1)-(7) were heated to 80°C to dissolve. (8)-(10) were added to the mixture and homogeneously blended to produce a moisturizing sunscreen cream.

Example 8

Preparation of ointment

		% by weight
(1)	Amine Derivative (la)	0.005
(2)	White petrolatum	Balance
(3)	Cholesteryl isostearate	3.0

PCT/JP92/01210

(4)	Liquid paraffin	10.0
•	Glyceryl ether	1.0
•	Glycerine	10.0

(1)-(6) were heated to 80°C to dissolve and cooled to produce an ointment.

Example 9

Preparation of face pack

	·	% by weight
(1)	Amine Derivative hydrochloride (1g')	0.05
(2)	Polyvinyl alcohol	15.0
-` ′. (3)	Sodium carboxymethyl cellulose	5.0
(4)	Propylene glycol	3.0
(5)	Ethanol	8.0
(6)	Purified water	67.5
(7)	Perfume	0.5
(8)	Preservative, antioxidant	q.s.

(1)-(8) were heated to 70°C to dissolve and cooled to produce a face pack.

Compositions for external skin care prepared in Examples 5-9 were all exhibited excellent effects of suppressing production of and extinction of wrinkles. They were effective in controlling incomplete keratinization, skin thickening, and abnormal lipid metabolism, and further in the restoration and constant maintenance of normal skin functions. Furthermore, these compositions did not cause red spots on the skin to develop,

WO 93/05763 PCT/JP92/01210

nor they were irritative to the skin.

Industrial Applicability

highly safe material.

The composition for external skin car of the present invention has an excellent effect of suppressing generation of or diminishing wrinkles, and exhibits an action of controlling incomplete keratinization, skin thickening, and abnormal lipid metabolism. In addition the composition is a

CLAIMS

 A composition for external skin care comprising an amine derivative of the following formula (1),

$$R^{1}-O-CH_{2}$$
 $CH-OH$
 $R^{2}-N-CH_{2}$
 $R^{3}-C$
 R^{4}
 R^{5}
 R^{6}
 R^{6}

wherein R^1 is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom or a hydrocarbon group having 1-10 carbon atoms, which may be substituted or unsubstituted by 1 or more hydroxy groups; or an acid addition salt thereof, in an amount from 0.0001 to less than 0.1% by weight.

- 2. The composition for external skin care according to Claim 1, wherein \mathbb{R}^1 in said formula (1) is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, \mathbb{R}^2 is a hydrogen atom, or a lower alkyl or a hydroxyalkyl group, and \mathbb{R}^3 , \mathbb{R}^4 , \mathbb{R}^5 , and \mathbb{R}^6 are individually a hydrogen atom.
- 3. The composition for external skin care according to Claim 1, wherein \mathbb{R}^1 in said formula (1) is a group represented by the following formula,

$$CH_3(CH_2)_mCH(CH_2)_n$$
-
 CH_3

wherein m+n is 11-17, m is 4-10, and n is 5-11, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom.

4. A method of improving wrinkles characterized by applying to the skin an amine derivative of the following formula (1),

$$R^{1}-O-CH_{2}$$
 $CH-OH$
 $R^{2}-N-CH_{2}$
 $R^{3}-C$
 R^{4}
 R^{5}
 R^{6}
 R^{6}

wherein R^1 is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom or a hydrocarbon group having 1-10 carbon atoms, which may be substituted or unsubstituted by 1 or more hydroxy groups; or an acid addition salt thereof.


- 5. A method of curing wrinkles according to Claim 4, wherein \mathbb{R}^1 in said formula (1) is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, \mathbb{R}^2 , \mathbb{R}^3 , \mathbb{R}^4 , \mathbb{R}^5 , and \mathbb{R}^6 are individually a hydrogen atom.
- 6. A method of curing wrinkles according to Claim 4, wherein \mathbb{R}^1 in said formula (1) is a group represented by the

following formula,

$$CH_3(CH_2)_mCH(CH_2)_n-CH_3$$

wherein m+n is 11-17, m is 4-10, and n is 5-11, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom.

7. A method of improving keratinization of the skin characterized by applying an amine derivative of the following formula (1),



wherein R^1 is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom or a hydrocarbon group having 1-10 carbon atoms, which may be substituted or unsubstituted by 1 or more hydroxy groups; or an acid addition salt thereof, to the skin.

8. A method of improving keratinization of the skin according to Claim 7, wherein R¹ in said formula (1) is a linear, branched, or cyclic saturated or unsaturated hydrocarbon group having 4-40 carbon atoms, R² is a hydrogen atom, or a lower alkyl or a lower hydroxyalkyl group, and

PCT/JP92/01210


 R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom.

9. A method of curing keratinization of the skin according to Claim 7, wherein \mathbb{R}^1 in said formula (1) is a group represented by the following formula,

$$\text{CH}_3(\text{CH}_2)_{\mathfrak{m}} \text{CH}(\text{CH}_2)_{\mathfrak{n}} - \\ \text{CH}_3$$

wherein m+n is 11-17, m is 4-10, and n is 5-11, and R^2 , R^3 , R^4 , R^5 , and R^6 are individually a hydrogen atom.

FIG. 1




Relative Amount of [3H] Thymidine Incorporation (%

Amount Added: 10 µM Amount Added: 100 µM

1 / 4

FIG. 2



Relative amount of $(^3\mathrm{H})$ Thymidine Amount Added: 10 juM Incorporation (%)

Amount Added: 100 µM

2 / 4

FIG. 3





FIG. 4



Dermal Thickness ($x10^{-2}$ mm)

International Application No

	F SUBJECT MATTER (if several classification				
According to Internations Int.C1. 5 A61K	al Patent Classification (IPC) or to both National	Classification and IPC			
Inc.or. 5 Address to					
II. FIELDS SEARCHED	Misleum Doc	imentation Searched?			
Classification System	William Doc	Classification Symbols			
Int.C1. 5	Int.C1. 5 A61K				
	Documentation Searched off to the Extent that such Documen	ner than Minimum Documentation its are Included in the Fields Searched ⁸			
	SIDERED TO BE RELEVANT ⁹		Relevant to Claim No.		
Category Citat	ion of Document, 11 with indication, where appro	priate, of the relevant passages 12	Resear to Claim No.		
21	A,0 282 816 (KAO CORPORAT September 1988 the whole document	ION)	1-9		
A PAT vol & 3	ENT ABSTRACTS OF JAPAN . 40, no. 12 (C-071)29 Ja IP,A,54 147 937 (KANEBO)	nuary 1980 19 November	1-9		
vol & 3 197 cit	ENT ABSTRACTS OF JAPAN 1. 31, no. 57 (C-068)22 De 19,A,54 135 233 (KANEBO) 29 30 ted in the application 31 abstract	cember 1979 20 October	1-9		
		-/			
1		, -/			
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "A" document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such document is combination being obvious to a person skilled in the art. "A" document member of the same patent family					
IV. CERTIFICATION		Date of Mailing of this International Set	urch Report		
•	Date of the Actual Completion of the International Search 20 JANUARY 1993 9 0, 02, 93				
International Searching Authority EUROPEAN PATENT OFFICE Signature of Authorized Officer FISCHER J.P.					

Form PCT/ISA/210 (second sheet) (Juneary 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)			
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.	
X,P	WO,A,9 206 982 (UNILEVER) 30 April 1992 see the whole document	1,4,7-8	
·			

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

JP 9201210 SA 64730

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.

The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20/01/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0282816	21-09-88	JP-A-	63216812	09-09-88
·		JP-A-	63218609	12-09-88
		JP-A-	63222107	16-09-88
•		JP-A-	63227513	2109-88
		JP-A-	63227514	21-09-88
		JP-A-	63297309	05-12-88
		JP-A-	1009905	13-01-89
	•	JP-A-	1009906	13-01-89
		JP-A-	1009907	13-01-89
		US-A-	4985547	15-01-91
		US-A-	5028416	02-07-91
		US-A-	5071971	10-12-91
		JP-A-	1079195	24-03-89
WO-A-9206982	30-04-92	AU-A-	8734391	20-05-92

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82